Ipidacrine (1 mg/kg, p.o., repeated and a single dose for 5 days) by repeated administration has more potent antiamnesic effects than by single administration in induced by nucleus basalis of meynert (NBM) induced rats[1].
Ipidacrine (10 mg/kg p.o., a single dose) significantly decreases spontaneous movements, which is more selective as an antiamnesic than either Tacrine (HY-111338) and E-2020 (HY-B0034) in rats[1].
Ipidacrine (6.7 mg/kg, intragastrically, daily for 14 days) leads to statistically more efficient evolving of intracavernous pressure (ICPmax)/maxipressure (MAP) compared with control group in Streptozotocin (STZ) (HY-13753)-induced diabetic rats[3].
| Animal Model: | Rats[1] |
| Dosage: | 1 mg/kg |
| Administration: | p.o., repeated and a single dose for 5 days |
| Result: | The repeated administration of ipidacrine improved amnesia induced by nucleus basalis of meynert (NBM) lesions in the passive avoidance task in rats. |
| Animal Model: | Rats[1] |
| Dosage: | 3, 10, 30 mg/kg |
| Administration: | p.o., a single dose |
| Result: | Decreased pupil size and increased salivation at 3 mg/kg, decreased spontaneous movements at 10 mg/kg and decreased body temperature and induced tremor at 30 mg/kg in rats. |
| Animal Model: | Rats with streptozotocin (STZ) (HY-13753) induced diabetes mellitus-induced erectile dysfunction (DMED)[1] |
| Dosage: | 6.7 mg/kg |
| Administration: | crushed, suspended in 1% starch solution and administered intragastrically daily for 14 days |
| Result: | Ipidacrine was as effective as sildenafil and could significantly improve DMED symptoms. |
![2,3,5,6,7,8-Hexahydro-1H-cyclopenta[b]quinolin-9-ylamine Structure](https://www.chemicalbook.com/CAS/GIF/62732-44-9.gif)
